KPV 10% OFF This Week | Free Shipping $450+

Luxara Labs | Mitochondrial Research Comparison

MOTS-c vs SS-31: Differences and Research Evidence

Two peptides connected to mitochondria, with different origins, mechanisms and evidence. Compare the science, understand its limits and review the documentation behind laboratory research materials.

By Luxara Labs · Published · Sources checked October 15, 2026

What is the difference between MOTS-c and SS-31?

MOTS-c is a mitochondrial-derived signaling peptide; SS-31 is a synthetic mitochondria-targeted peptide. MOTS-c research examines metabolic regulation and cellular stress responses. SS-31, also known as elamipretide, is studied for interactions with cardiolipin in the inner mitochondrial membrane. Their shared mitochondrial theme does not make them interchangeable. [1] [2] [4]

Explore research peptides with documentation in view

Browse the Luxara Labs catalog, compare available products and review supporting lab reports before sourcing.

Shop Peptides

For laboratory research use only. Not for human or animal use.

MOTS-c vs SS-31 at a glance

Structural and research differences
Comparison MOTS-c SS-31
Peptide class Mitochondrial-derived peptide Synthetic mitochondria-targeted tetrapeptide
Chain length 16 amino acids 4 amino acids
Origin Sequence encoded within mitochondrial 12S rRNA Designed synthetic sequence
Main research emphasis Metabolic signaling, stress adaptation and gene regulation Cardiolipin interactions, membrane biology and bioenergetics
Evidence examples Cell and animal experiments; human measurements around exercise Membrane experiments, animal studies and disease-specific human trials
Important distinction Endogenous peptide observations do not validate administration of a purchased material Elamipretide drug-product findings do not validate independently sourced SS-31 vials
Luxara laboratory material MOTS-c product details SS-31 product details

Scientific context: references 1, 2, 3 and 4. This is a literature comparison, not a head-to-head trial.

Key takeaways

  • The difference is mechanistic, not simply a question of which peptide is stronger.
  • Human observations, animal experiments and randomized clinical trials answer different questions.
  • Evidence for each peptide separately does not establish a benefit from combining them.
  • Supplier identity, batch documentation and analytical methods remain separate verification tasks.

For detailed individual profiles, see the MOTS-c Canada research guide and SS-31 Canada research guide.

How their research mechanisms differ

MOTS-c: metabolic and stress signaling

The original MOTS-c work linked the peptide to metabolic regulation in experimental models. Subsequent cellular research reported movement into the nucleus during metabolic stress and AMPK-dependent regulation of stress-responsive gene expression. [1] [2]

The scientific question is how a mitochondrial-derived signal participates in cellular adaptation. It is broader than a claim that the peptide simply increases energy.

SS-31: membrane and cardiolipin biology

Experimental work examined SS-31 interactions with cardiolipin and cytochrome c, including effects on electron transfer and ATP synthesis in mitochondrial preparations. These experiments support a membrane-focused mechanism. [4]

The scientific question is how those interactions influence mitochondrial function in a defined model. A mechanistic finding alone does not establish a clinical outcome.

Plain-English distinction: MOTS-c is studied as a signal involved in cellular adaptation. SS-31 is studied through interactions with mitochondrial membrane components. Neither description establishes that one is universally better.

Which has more human research?

Elamipretide has a more developed clinical evidence base than the MOTS-c research described here. That does not establish superiority in a shared indication. The molecules have not been compared against each other in the studies cited on this page.

MOTS-c: distinguish human measurements from treatment trials

A 2021 study combined cellular and mouse experiments with measurements of endogenous MOTS-c around exercise in humans. Human exercise measurements are not a trial showing that administered MOTS-c improves human performance. [3]

This distinction prevents a common reasoning error: an association involving a molecule produced in the body does not establish the effects of giving an externally supplied version.

SS-31: clinical findings depend on the condition and endpoint

The randomized Phase 3 MMPOWER-3 trial evaluated elamipretide in primary mitochondrial myopathy. It did not meet its primary endpoints for six-minute walking distance and fatigue at 24 weeks. That result belongs alongside positive mechanistic findings when assessing the evidence. [5]

Is SS-31 FDA approved?

On September 19, 2025, the FDA granted accelerated approval to Forzinity, an elamipretide drug product, for Barth syndrome in patients weighing at least 30 kg . The approval was based on a muscle-strength measure, with a confirmatory trial required. [6]

That is a specific U.S. drug approval. It is not approval of SS-31 sold by research suppliers, a general longevity indication or authorization in Canada. Luxara Labs SS-31 is supplied for laboratory research only.

Does combining MOTS-c and SS-31 have established benefits?

The cited studies do not establish a combined clinical benefit. Different mechanisms can justify asking a research question, but they do not demonstrate synergy, compatibility or safety together.

A claim about a combination needs evidence on that combination: the actual materials, model, comparators, endpoints and analysis. Separate positive findings cannot be added together to predict a larger effect.

Our peptide blends vs single peptides guide explains the documentation and interpretation issues that arise when multiple compounds are discussed together.

Are these the same as NAD+ or L-Carnitine?

No. Grouping products under a cellular-energy heading does not make their chemistry or evidence interchangeable. For separate background, see the NAD+ research guide and L-Carnitine research guide. This comparison remains focused on MOTS-c and SS-31.

Where to buy peptides in Canada: what to verify first

Once the research distinction is clear, the next question is whether the supplied material is adequately documented. Our Where to Buy Peptides in Canada guide explains how to evaluate suppliers through testing, traceability, fulfillment and accessible support.

Luxara Labs provides a research peptide shop and public third-party lab results and COAs. Review the relevant report alongside each product listing rather than relying on a general purity statement.

Documentation checks for either peptide
Check Question to answer Luxara resource
Identity What analytical evidence supports the stated compound? How to Read a COA
Purity and content Does the report distinguish chromatographic purity from measured amount? Purity standards
Traceability Do the product, strength and lot details match the report? Lab Results and COAs
Handling What storage information applies to the material and format? Storage and handling
Fulfillment Where are shipping and tracking expectations explained? Canadian shipping guide

A 99%+ purity statement is not a complete quality profile. Chromatographic purity does not, by itself, establish vial content, sterility, endotoxin levels or suitability for human use. Review what was actually measured and which questions remain unanswered.

Review the two product listings

Use the MOTS-c research product page and SS-31 research product page to compare current strengths, prices and product details. Then cross-check the supporting documentation. Available options and pricing are maintained on the product pages.

Related Luxara research and quality resources

Understand the research

Evaluate the supplier

For jurisdiction-specific background, review research-use regulations in Canada or U.S. peptide research regulations. A research-use label does not replace the need to meet applicable requirements.

MOTS-c vs SS-31 FAQ

Are MOTS-c and SS-31 the same peptide?

No. MOTS-c is a 16-amino-acid mitochondrial-derived peptide. SS-31 is a synthetic four-amino-acid peptide also known as elamipretide. [1] [4]

Which is better for mitochondrial research?

That depends on the scientific question. MOTS-c literature emphasizes metabolic and stress signaling; SS-31 literature emphasizes membrane interactions and bioenergetics. The cited evidence does not establish a universal winner.

Does SS-31 have more human evidence?

Elamipretide has randomized clinical-trial evidence and a specific FDA-approved drug product. Those findings must be interpreted by indication and do not validate research-supplier vials. [5] [6]

Does the research prove a MOTS-c and SS-31 stack works?

No combined clinical benefit is established by the studies cited here. Mechanistic differences alone do not prove synergy or safety together.

Where can Canadian researchers review products and COAs?

Start with the Luxara Labs shop, the Lab Results page and our Canadian peptide supplier guide. Match the relevant report to the product and lot.

Primary references and editorial transparency

  1. Lee C et al. Original MOTS-c metabolic-homeostasis study. Cell Metabolism. 2015. DOI: 10.1016/j.cmet.2015.02.009.
  2. Kim KH et al. MOTS-c nuclear translocation and stress-responsive gene regulation. Cell Metabolism. 2018. DOI: 10.1016/j.cmet.2018.06.008.
  3. MOTS-c exercise, muscle-homeostasis and physical-capacity study. Nature Communications. 2021. DOI: 10.1038/s41467-020-20790-0.
  4. Birk AV et al. SS-31, cardiolipin and cytochrome c mechanistic study. British Journal of Pharmacology. 2014. DOI: 10.1111/bph.12468.
  5. Karaa A et al. MMPOWER-3 randomized clinical trial of elamipretide. Neurology. 2023. DOI: 10.1212/WNL.0000000000207402.
  6. U.S. Food and Drug Administration. Forzinity accelerated approval for Barth syndrome. September 19, 2025.

Editorial disclosure: Luxara Labs supplies research materials and has a commercial interest in the products discussed. This page is a literature-based comparison, not original clinical research or independent medical review. Sources are linked so readers can evaluate the underlying evidence. See our research methodology or contact us about a correction.

Compare products. Review the evidence. Verify the documentation.

Explore MOTS-c, SS-31 and the wider Luxara Labs catalog for laboratory research, with product details and supporting COA resources.

Shop Peptides

For laboratory research use only. Not for human or animal use.

Research-use notice: Luxara Labs materials are not intended for human or animal use, diagnosis or treatment. Published findings and drug approvals do not establish the clinical suitability of independently supplied research materials.